|
1
|
Abedinpour P, Baron VT, Welsh J, et al:
Regression of prostate tumors upon combination of hormone ablation
therapy and celecoxib in vivo. Prostate. 71:813–823. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ahmad A, Aboukameel A, Kong DJ, et al:
Phosphoglucose isomerase/autocrine motility factor mediates
epithelial-mesenchymal transition regulated by miR-200 in breast
cancer cells. Cancer Res. 71:3400–3409. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Akkoc A, Inan S and Sonmez G: Matrix
metalloproteinase (MMP-2 and MMP-9) and steroid receptor
expressions in feline mammary tumors. Biotech Histochem.
87:312–319. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Amente S, Zhang J, Lavadera ML, et al: Myc
and PI3K/AKT signaling cooperatively repress FOXO3a-dependent PUMA
and GADD45a gene expression. Nucleic Acids Res. 39:9498–9507. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Asirvatham AJ, Gregorie CJ, Hu Z, et al:
MicroRNA targets in immune genes and the Dicer/Argonaute and ARE
machinery components. Mol Immunol. 45:1995–2006. 2008. View Article : Google Scholar
|
|
6
|
Bean GR, Ganesan YT, Dong YY, et al: PUMA
and BIM are required for oncogene inactivation-induced apoptosis.
Sci Signal. 6:ra202013.PubMed/NCBI
|
|
7
|
Campone M, Noel B, Couriaud C, et al:
c-Myc dependent expression of proapoptotic Bim renders
HER2-overexpressing breast cancer cells dependent on anti-apoptotic
Mcl-1. Mol Cancer. 10:1102011. View Article : Google Scholar
|
|
8
|
Catto JW, Alcaraz A, Bjartell AS, et al:
MicroRNA in prostate, bladder, and kidney cancer: a systematic
review. Eur Urol. 59:671–681. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chang LY, Lin YC, Mahalingam J, et al:
Tumor-derived chemokine CCL5 enhances TGF-beta-mediated killing of
CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res.
72:1092–1102. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen L, Zhang J, Han L, et al:
Downregulation of miR-221/222 sensitizes glioma cells to
temozolomide by regulating apoptosis independently of p53 status.
Oncol Rep. 27:854–860. 2012.
|
|
11
|
Chopin D, Barei-Moniri R, Maille P, et al:
Human urinary bladder transitional cell carcinomas acquire the
functional Fas ligand during tumor progression. Am J Pathol.
162:1139–1149. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Di Martino MT, Gulla A, Cantafio ME, et
al: In vitro and in vivo antitumor activity of miR-221/222
inhibitors in multiple myeloma. Oncotarget. 4:242–255.
2013.PubMed/NCBI
|
|
13
|
Eissa S, Badr S, Elhamid SA, et al: The
value of combined use of survivin mRNA and matrix metalloproteinase
2 and 9 for bladder cancer detection in voided urine. Dis Markers.
34:57–62. 2013. View Article : Google Scholar :
|
|
14
|
Eissa S, Shabayek MI, Ismail MF, et al:
Diagnostic evaluation of apoptosis inhibitory gene and tissue
inhibitor matrix metalloproteinase-2 in patients with bladder
cancer. IUBMB Life. 62:394–399. 2010.PubMed/NCBI
|
|
15
|
Errami Y, Naura AS, Kim H, et al:
Apoptotic DNA fragmentation may be a cooperative activity between
caspase-activated deoxy-ribonuclease and the poly(ADP-ribose)
polymerase-regulated DNAS1L3, an endoplasmic reticulum-localized
endonuclease that translocates to the nucleus during apoptosis. J
Biol Chem. 288:3460–3468. 2013. View Article : Google Scholar :
|
|
16
|
Follis AV, Chipuk JE, Fisher JC, et al:
PUMA binding induces partial unfolding within BCL-xL to disrupt p53
binding and promote apoptosis. Nat Chem Biol. 9:163–168. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Foster RR, Satchell SC, Seckley J, et al:
VEGF-C promotes survival in podocytes. Am J Physiol Renal Physiol.
291:F196–F207. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Garcia-Lora A, Algarra I and Garrido F:
MHC class I antigens, immune surveillance, and tumor immune escape.
J Cell Physiol. 195:346–355. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gottardo F, Liu CG, Ferracin M, et al:
Micro-RNA profiling in kidney and bladder cancers. Urol Oncol.
25:387–392. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Holoch PA and Griffith TS: TNF-related
apoptosis-inducing ligand (TRAIL): a new path to anti-cancer
therapies. Eur J Pharmacol. 625:63–72. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Igney FH and Krammer PH: Immune escape of
tumors: apoptosis resistance and tumor counterattack. J Leukoc
Biol. 71:907–920. 2002.PubMed/NCBI
|
|
22
|
Inman BA, Sebo TJ, Frigola X, et al: PD-L1
(B7-H1) expression by urothelial carcinoma of the bladder and
BCG-induced granulomata: associations with localized stage
progression. Cancer. 109:1499–1505. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jayasinghe C, Simiantonaki N,
Michel-Schmidt R, et al: Endothelial VEGFR-3 expression in
colorectal carcinomas is associated with hematogenous metastasis.
Oncol Rep. 22:1093–1100. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jayasooriya RG, Choi YH, Moon SK, et al:
Methanol extract of Hydroclathrus clathratus suppresses matrix
metalloproteinase-9 in T24 bladder carcinoma cells by suppressing
the NF-kappaB and MAPK pathways. Oncol Rep. 27:541–546. 2012.
|
|
25
|
Jemal A, Bray F, Center MM, et al: Global
cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jin X, Xiao LJ, Zhang XS, et al: Apotosis
in ovary. Front Biosci (Schol Ed). 3:680–697. 2011. View Article : Google Scholar
|
|
27
|
Kajiya K, Sawane M, Huggenberger R, et al:
Activation of the VEGFR-3 pathway by VEGF-C attenuates UVB-induced
edema formation and skin inflammation by promoting
lymphangiogenesis. J Invest Dermatol. 129:1292–1298. 2009.
View Article : Google Scholar
|
|
28
|
Khong HT and Restifo NP: Natural selection
of tumor variants in the generation of ‘tumor escape’ phenotypes.
Nat Immunol. 3:999–1005. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Krebs R, Tikkanen JM, Ropponen JO, et al:
VEGF-C/VEGFR-3 signaling regulates inflammatory response in
development of obliterative airway disease. J Heart Lung Transpl.
30:S1182011. View Article : Google Scholar
|
|
30
|
Langers AMJ, Verspaget HW, Hawinkels LJAC,
et al: MMP-2 and MMP-9 in normal mucosa are independently
associated with outcome of colorectal cancer patients. Br J Cancer.
106:1495–1498. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li XQ, Dang XG and Sun XB: Expression of
survivin and VEGF-C in breast cancer tissue and its relation to
lymphatic metastasis. Eur J Gynaecol Oncol. 33:178–182.
2012.PubMed/NCBI
|
|
32
|
Li Y, Yang K, Mao Q, et al: Inhibition of
TGF-beta receptor I by siRNA suppresses the motility and
invasiveness of T24 bladder cancer cells via modulation of
integrins and matrix metallopro-teinase. Int Urol Nephrol.
42:315–323. 2010. View Article : Google Scholar
|
|
33
|
Lund AW, Duraes FV, Hirosue S, et al:
VEGF-C promotes immune tolerance in B16 melanomas and
cross-presentation of tumor antigen by lymph node lymphatics. Cell
Rep. 1:191–199. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Martins SF, Garcia EA, Luz MA, et al:
Clinicopathological correlation and prognostic significance of
VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal
cancer. Cancer Genomics Proteomics. 10:55–67. 2013.PubMed/NCBI
|
|
35
|
Min Y, Ghose S, Boelte K, et al:
C/EBP-delta regulates VEGF-C autocrine signaling in
lymphangiogenesis and metastasis of lung cancer through HIF-1
alpha. Oncogene. 30:4901–4909. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Neal MD, Sodhi CP, Jia H, et al: The P53
upregulated modulator of apoptosis (Puma) regulates Tlr4-mediated
enterocyte apopotosis in the pathogenesis of necrotizing
enterocolitis. Shock. 35:60. 2011.
|
|
37
|
Newton MR, Askeland EJ, Andresen ED, et
al: Anti-interleukin-10R1 monoclonal antibody in combination with
BCG is protective against bladder cancer metastasis in a murine
orthotopic tumor model and demonstrates systemic specific antitumor
immunity. Clin Exp Immunol. 177:261–268. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Niederkorn JY: Immune escape mechanisms of
intraocular tumors. Prog Retin Eye Res. 28:329–347. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Okada A: Roles of matrix
metalloproteinases and tissue inhibitor of metalloproteinase (TIMP)
in cancer invasion and metastasis. Gan To Kagaku Ryoho.
26:2247–2252. 1999.
|
|
40
|
Okada R, Nagaosa K, Kuraishi T, et al:
Apoptosis-dependent externalization and involvement in apoptotic
cell clearance of DmCaBP1, an endoplasmic reticulum protein of
Drosophila. J Biol Chem. 287:3138–3146. 2012. View Article : Google Scholar :
|
|
41
|
Olofsson B, Jeltsch M, Eriksson U, et al:
Current biology of VEGF-B and VEGF-C. Curr Opin Biotech.
10:528–535. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Piazzolla G, Nuzzaci M, Vitti A, et al:
Apoptotic effects of a chimeric plant virus carrying a mimotope of
the hepatitis C virus hypervariable region 1: role of caspases and
endoplasmic reticulum-stress. J Clin Immunol. 32:866–876. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Planaguma L, Liljestrom M, Alameda F, et
al: Matrix metalloproteinase-2 and matrix metalloproteinase-9
codistribute with transcription factors RUNX1/AML1 and ETV5/ERM at
the invasive front of endometrial and ovarian carcinoma. Hum
Pathol. 42:57–67. 2011. View Article : Google Scholar
|
|
44
|
Poyet C, Banzola I, Linto T, et al:
Bladder cancer micro-environment influences maturation signature in
lymphatic endothelial cells (LECs) by VEGF-C. Eur Urol (Suppl).
11:E906–U905. 2012. View Article : Google Scholar
|
|
45
|
Rabinovich GA, Gabrilovich D and Sotomayor
EM: Immunosuppressive strategies that are mediated by tumor cells.
Annu Rev Immunol. 25:267–296. 2007. View Article : Google Scholar
|
|
46
|
Saharinen P, Eklund L, Pulkki K, et al:
VEGF and angiopoietin signaling in tumor angiogenesis and
metastasis. Trends Mol Med. 17:347–362. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sato H, Takino T and Miyamori H: Roles of
membrane-type matrix metalloproteinase-1 in tumor invasion and
metastasis. Cancer Sci. 96:212–217. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Seiler R, Thalmann GN and Fleischmann A:
MMP-2 and MMP-9 in lymph-node-positive bladder cancer. J Clin
Pathol. 64:1078–1082. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Senger DR, Van de Water L, Brown LF, et
al: Vascular permeability factor (VPF, VEGF) in tumor biology.
Cancer Metastasis Rev. 12:303–324. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Siddle H, Kreiss A, Tovab C, et al: Immune
escape strategies of a contagious cancer, devil facial tumour
disease. Mol Immunol. 51:302012. View Article : Google Scholar
|
|
51
|
Siriwardena BSMS, Kudo Y, Ogawa I, et al:
VEGF-C is associated with lymphatic status and invasion in oral
cancer. J Clin Pathol. 61:103–108. 2008. View Article : Google Scholar
|
|
52
|
Stanton MJ, Dutta S, Zhang H, et al:
Autophagy control by the VEGF-C/NRP-2 axis in cancer and its
implication for treatment resistance. Cancer Res. 73:160–171. 2013.
View Article : Google Scholar :
|
|
53
|
Sullu Y, Demirag GG, Yildirim A, et al:
Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive
ductal carcinoma of the breast. Pathol Res Pract. 207:747–753.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Takano S: Glioblastoma angiogenesis: VEGF
resistance solutions and new strategies based on molecular
mechanisms of tumor vessel formation. Brain Tumor Pathol. 29:73–86.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Takizawa H, Kondo K, Fujino H, et al: The
balance of VEGF-C and VEGFR-3 mRNA is a predictor of lymph node
metastasis in non-small cell lung cancer. Br J Cancer. 95:75–79.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Torii A, Kodera Y, Ito M, et al: Matrix
metalloproteinase 9 in mucosally invasive gastric cancer. Gastric
Cancer. 1:142–145. 1998. View Article : Google Scholar
|
|
57
|
Tsubata T: Apotosis of mature B cells. Int
Rev Immunol. 18:347–365. 1999. View Article : Google Scholar
|
|
58
|
Valtola R, Salven P, Heikkila P, et al:
VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in
breast cancer. Am J Pathol. 154:1381–1390. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Vasala K, Paakko P and
Turpeenniemi-Hujanen T: Matrix metalloproteinase-9 (MMP-9)
immunoreactive protein in urinary bladder cancer: a marker of
favorable prognosis. Anticancer Res. 28:1757–1761. 2008.PubMed/NCBI
|
|
60
|
Vasala K and Turpeenniemi-Hujanen T: Serum
tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix
metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as
prognostic markers in bladder cancer. Clin Biochem. 40:640–644.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wang F, Li HM, Wang HP, et al:
siRNA-mediated knockdown of VEGF-A, VEGF-C and VEGFR-3 suppresses
the growth and metastasis of mouse bladder carcinoma in vivo. Exp
Ther Med. 1:899–904. 2010.PubMed/NCBI
|
|
62
|
Wang Z, Li R, Zhou B, et al: Relationships
of human laryngeal squamous cell carcinomas with the expression of
VEGF-C and VEGFR-3. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi.
26:842–846. 2009.(In Chinese). PubMed/NCBI
|
|
63
|
Wu K, Wang X, Xie Z, et al: Glutathione
S-transferase P1 gene polymorphism and bladder cancer
susceptibility: an updated analysis. Mol Biol Rep. 40:687–695.
2013. View Article : Google Scholar
|
|
64
|
Yerlikaya A, Okur E and Ulukaya E: The
p53-independent induction of apoptosis in breast cancer cells in
response to proteasome inhibitor bortezomib. Tumor Biol.
33:1385–1392. 2012. View Article : Google Scholar
|
|
65
|
Yonemura Y, Fushida S, Bando E, et al:
Lymphangiogenesis and the vascular endothelial growth factor
receptor (VEGFR)-3 in gastric cancer. Eur J Cancer. 37:918–923.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Yu J and Zhang L: No PUMA, no death:
implications for p53-dependent apoptosis. Cancer Cell. 4:248–249.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Yu J, Zhang L, Hwang PM, et al: PUMA
induces the rapid apoptosis of colorectal cancer cells. Mol Cell.
7:673–682. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zhang C, Zhang J, Zhang A, et al: PUMA is
a novel target of miR-221/222 in human epithelial cancers. Int J
Oncol. 37:1621–1626. 2010.PubMed/NCBI
|
|
69
|
Zhang CZ, Zhang JX, Zhang AL, et al:
MiR-221 and miR-222 target PUMA to induce cell survival in
glioblastoma. Mol Cancer. 9:2292010. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Zhang LN, Li JY and Xu W: A review of the
role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug
resistance of chronic lymphocytic leukemia. Cancer Gene Ther.
20:1–7. 2013. View Article : Google Scholar
|
|
71
|
Zhao ZW, Wang JJ, Tang JS, et al: JNK- and
Akt-mediated Puma expression in the apoptosis of
cisplatin-resistant ovarian cancer cells. Biochem J. 444:291–301.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Zheng M, Zhang Q, Joe Y, et al: Curcumin
induces apoptotic cell death of activated human CD4+ T
cells via increasing endoplasmic reticulum stress and mitochondrial
dysfunction. Int Immunopharmacol. 15:517–523. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Zhu X, Tai W, Shi W, et al: Matrix
metalloproteinase-9 silencing by RNA interference promotes the
adhesive-invasive switch in HT1080 human fibrosarcoma cells. Clin
Lab. 58:313–322. 2012.PubMed/NCBI
|
|
74
|
Nakano K and Vousden KH: PUMA, a novel
proapoptotic gene, is induced by p53. Mol Cell. 7:683–694. 2001.
View Article : Google Scholar : PubMed/NCBI
|
